Pharmaceutical firms stalling on new plans

Published: 2008-12-09 07:00:00

Updated: 2008-12-09 07:00:00

Reflecting increasing uncertainty in the global economy with protracted weakening of the won against the U.S. dollar and the Japanese yen, major Korean pharmaceutical manufacturers are delaying the formulation of their business plans for next year.

The won has fallen more than 35 percent agai...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK